Welcome to our dedicated page for Nutriband SEC filings (Ticker: NTRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutriband Inc. (NTRB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutriband uses current reports on Form 8-K to furnish material information, including press releases that describe developments in its AVERSA abuse-deterrent transdermal technology platform and its lead product candidate, an abuse-deterrent fentanyl transdermal system.
Through these filings, investors can review how Nutriband reports regulatory interactions with the U.S. Food and Drug Administration, such as meetings to discuss Chemistry, Manufacturing, and Controls plans, the 505(b)(2) NDA pathway for AVERSA Fentanyl, and planned in vitro studies to characterize abuse-deterrent properties. Filings may also reference intellectual property actions, including patent allowances and provisional patent applications intended to strengthen and extend protection for the AVERSA technology.
Nutriband’s SEC documents can further detail corporate and capital structure events, such as preferred stock dividends linked to potential future FDA approval of AVERSA Fentanyl, warrant-related information, and transactions like the sale of a majority interest in subsidiary Pocono Pharmaceutical to EarthVision Bio. These filings provide formal context around how the company allocates resources toward the development of its transdermal pharmaceutical portfolio.
On Stock Titan, Nutriband filings are updated as they are made available through EDGAR, and AI-powered tools summarize key points from lengthy documents. Users can quickly identify the main topics in each filing, such as regulatory strategy, product development milestones, or financing-related disclosures, and then drill down into the full text for detailed review. This structure helps investors and researchers understand how Nutriband presents its business, technology, and risk factors in its official SEC communications.
Nutriband Inc. reported modest revenue growth but significantly higher losses for the quarter and nine months ended October 31, 2025. Revenue for the quarter fell to
Despite a nine‑month gross profit of
Nutriband ended the period with cash of
NutriBand Inc. (NTRB) CEO and director Gareth Sheridan, who is also a 10% owner, reported his annual holdings for the fiscal year ended 01/31/2025. He beneficially owned 1,761,667 shares of NutriBand common stock in direct ownership at year-end.
Sheridan also reported stock options as derivative securities. On 03/20/2024, he received stock options for 97,500 shares with a $2.61 exercise price, expiring on 03/20/2027. On 01/29/2025, he received additional stock options for 29,333 shares with a $8.07 exercise price, expiring on 01/29/2028. Following these transactions, he held 251,000 stock options in total, all reported as directly owned.
NutriBand (NTRB) CFO Gerald Goodman filed a Form 5 for the fiscal year ended 01/31/2025, reporting year-end holdings and prior transactions under Section 16. The filing shows 66,085 shares of common stock beneficially owned at fiscal year-end, held directly.
Reported transactions include: acquisition of 60,085 common shares at $1.93 on 10/27/2023; a warrant at $1.93 tied to 60,085 underlying shares with an expiration date of 10/27/2026; a stock option grant for 75,000 shares at $1.93 on 03/19/2024 expiring 03/19/2027; and a stock option grant for 17,667 shares at $7.34 on 01/23/2025 expiring 01/23/2028. Ownership is indicated as direct for the securities listed.
Nutriband Inc. filed a prospectus supplement updating its 424(b)(3) prospectus for public warrants covering up to 910,904 shares of common stock. The outstanding warrants stem from the company’s October 2021 unit offering and are immediately exercisable at an adjusted exercise price of $6.43 per share.
As of October 19–20, 2025, 910,904 warrants remained outstanding and trade on Nasdaq as NTRBW. On October 17, 2025, the last reported sale prices were $7.48 per share for common stock and $2.50 per warrant. Shares outstanding were 12,034,883 as of September 8, 2025; this is a baseline figure, not the amount being offered.
The supplement also incorporates the company’s latest Form 10-Q, which showed revenue of $622,452 for the quarter ended July 31, 2025 and cash and cash equivalents of $6,995,101 as of that date.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
